ArticleAmerican journal of translational research2025
Superior visual quality outcomes with compound tropicamide eye drops in treating juvenile pseudomyopia.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of Compound Tropicamide (Trop) Eye Drops on the visual quality in juvenile pseudomyopia patients.
methodsData from 111 juvenile pseudomyopia patients treated between September 2019 and September 2022 were reviewed in this retrospective study, including 50 cases treated with Atropine Sulfate Ophthalmic Gel (control group) and 61 with Compound Trop Eye Drops (research group). Clinical efficacy, amplitude of accommodation (AA), uncorrected visual acuity (UCVA), intraocular pressure (IOP), axial length (AL), symptom improvement, complications, and quality of life were compared. Risk factors for visual quality improvement were analyzed using Logistic regression.
resultsThe research group demonstrated significantly higher treatment efficacy compared to the control group (P>0.05). Post-treatment, AA, IOP, and AL decreased notably in the research group compared to baseline and the control group (all P<0.05). UCVA and quality of life scores improved significantly in the research group (both P<0.05). Recovery indicators, including resolution of dizziness, alleviation of ocular soreness, and vision recovery, were significantly shorter in the research group (all P<0.05). Both groups had similar complication rates, including dry mouth, facial blushing, conjunctival congestion, and transient tachycardia (P>0.05). The research group reported superior post-treatment quality of life across all domains (all P<0.05). Logistic regression showed that gender, age, disease duration, family history of myopia, education level, AA, UCVA, and treatment method were not significant risk factors for visual quality improvement (all P>0.05).
conclusionCompound Trop Eye Drops effectively enhances visual function and quality of life in juvenile pseudomyopia patients, with a safety profile comparable to low-dose atropine, offering potential clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.